PubMed: Background Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 receptor agonists on erectile dysfunction is unknown. We aimed to assess the incidence, prevalence, and progression of erectile dysfunction in men treated with dulaglutide compared with placebo, and to determine whether dulaglutide's effect on erectile dysfunction was consistent with its effect on other diabetes-related outcomes. Men and women aged older than 50 years with type 2 diabetes, who had either a previous cardiovascular event or cardiovascular risk factors, were randomly assigned to receive either dulaglutide or placebo. Participating cukorbetegség térdfájás were offered the opportunity to complete the standardised International Index of Erectile Function IIEF questionnaire at baseline, 2 years, 5 years, and study end.
PubMed: Background Cardiovascular outcome trials have suggested that glucagon-like peptide 1 GLP-1 receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researching cardiovascular events with a weekly incretin in diabetes REWIND trial.
Methods REWIND was a multicentre, randomised, double-blind, placebo-controlled trial done at sites in 24 countries. Participants were randomly assigned to weekly subcutaneous injections of either masked dulaglutide 1.
Randomisation was done by a computer-generated random code with an interactive web response system with stratification by site. Participants, investigators, the trial leadership, and all other personnel were masked to treatment allocation until the trial was completed and the database was locked.
Go to: References 1. Prediabetes: a high-risk state for diabetes development. Diabetes Prevention Program Research Group The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the diabetes prevention program. Diabet Med.
During the treatment period, participants in both groups were instructed to inject study drug on the same day at around the same time, each week.
Strokes were categorised as fatal or non-fatal, and as either ischaemic, haemorrhagic, or undetermined.
Stroke severity was assessed using the modified Rankin scale. Participants were seen at 2 weeks, 3 months, 6 months, and then every 3 months for drug dispensing and every 6 months for detailed assessments, until confirmed primary outcomes accrued. The primary endpoint was the diabétesz diabéteszes retinopátia occurrence of any component of the composite outcome, which comprised non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular or unknown causes.
All analyses were done according to an intention-to-treat strategy that included all randomly assigned participants, irrespective of adherence. The trial is registered with ClinicalTrials. During a median follow-up of 5. Dulaglutide reduced ischaemic stroke 0.
Dulaglutide also reduced the composite of non-fatal stroke or all-cause death 0. The degree of disability after stroke did not differ by treatment group. Interpretation Long-term dulaglutide use might reduce clinically relevant ischaemic stroke in people with type 2 diabetes but does not affect stroke severity.
Copyright C Elsevier Ltd. All rights reserved.